Brief: Mauna Kea Cellvizio Demonstrates Superior Identification Of Patients At Risk For Esophageal Cancer
April 13 (Reuters) - MAUNA KEA TECHNOLOGIES SAS MKEA.PA :
* MAUNA KEA TECHNOLOGIES’ CELLVIZIO® DEMONSTRATES SUPERIOR
IDENTIFICATION OF PATIENTS AT RISK FOR ESOPHAGEAL CANCER
COMPARED TO CURRENT DIAGNOSTIC STANDARD
* RESULTS FROM NEW CLINICAL STUDY THAT ENROLLED 172 PATIENTS
AT 8
NON-ACADEMIC CENTERS IN UNITED-STATES
Source text for Eikon: ID:nBw4xSYLga
Further company coverage: MKEA.PA
(Gdynia Newsroom)
((gdynia.newsroom@thomsonreuters.com; +48 58 772 0920;))
Recent news on Mauna Kea Technologies SA
See all newsBrief: Mauna Kea Technologies Confirms Trajectory Toward Profitability By Year-End 2027
Brief: Mauna Kea Technologies Announces Results Of Its Combined General Meeting
French and Benelux stocks-Factors to watch 21 Nov
Brief: Mauna Kea Technologies Receives NMPA Regulatory Approval In China For Its Next-Generation Cellvizio Platform
Europe Research Roundup: Craneware, Croda, Genus